Patent · US Active

HCV NS3 protease inhibitors

US8987195B2 · kind B2 · utility

0Cited by

0References

27Claims

0Family size

Assignees

Merck Sharp & Dohme LLC · US
Merck Canada Inc. · CA

Inventors

Thomas Bara · Linden, US
Sathesh Bhat · Jersey City, US
Dipshikha Biswas · Woodbridge, US
Linda Brockunier · Orange, US
Duane A. Burnett · Wayland, US
Samuel Chackalamannil · Califon, US
Mariappan V. Chelliah · Edison, US
Austin Chih-Yu Chen · San Marcos, US
Martin C. Clasby · Plainsboro, US
Vince J. Colandrea · New Brunswick, US
Zhuyan Guo · Scotch Plains, US
Yongxin Han · Kirkland, CA
Charles Lee Jayne · Staten Island, US
Hubert Josien · Hoboken, US
Karen Marcantonio · New York, US
Shouwu Miao · Edison, US
Santhosh F. Neelamkavil · Edison, US
Patrick A. Pinto · Mine Hill, US
Murali Rajagopalan · Edison, US
Unmesh Shah · Green Brook, US
Francisco Velazquez · Clinton, US
Srikanth Venkatraman · Fords, US
Yan Xia · Edison, US

Key dates

Filing date	Aug 6, 2013
Grant date	Mar 24, 2015
Priority date	—
Expiry date	Aug 6, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/22
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.